NRAS activating mutations occur in 15-25% of melanoma patients. However, this subtype is more aggressive and refractory to current treatment modalities, including targeted MEK inhibitors, immunotherapies, and the recently emerging RAS inhibitors. Accordingly, identifying novel therapeutic targets an...
ORGANISM(S): Homo sapiens (Human)
